Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
June 21, 2024 08:05 ET | Starton Therapeutics
100% of patients enrolled achieved a partial response or betterMilder and less frequent drug-related adverse events were observed compared to those associated with Revlimid®No grade 3 or greater...
Antion Logo - RGB - Web version-01.png
Antion Biosciences announces development of safety-enhanced and off-the-shelf CAR T-cells for autoimmune disease
May 22, 2024 06:55 ET | ANTION BIOSCIENCES SA
Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases
NurExone logo2.png
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
March 08, 2024 16:05 ET | NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone logo2.png
NurExone’s Intellectual Property Portfolio Expands
February 20, 2024 16:05 ET | NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone logo2.png
NurExone Launches Licensing Efforts for ExoTherapy Platform
February 14, 2024 16:20 ET | NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
Yiviva and AstraZeneca Strategic Collaboration Memorandum Signing Ceremony
Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
February 05, 2024 09:00 ET | Yiviva
NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed...
Starton Therapeutics Announces STARTICLES Filing
January 17, 2024 15:12 ET | Starton Therapeutics
STARTICLES, referring to proprietary and novel solid-state particulates suspended within a drug-in-adhesive patch for delivery of active pharmaceutical ingredients (API) developed by Starton...
astrivax_high resolution.png
AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine
December 12, 2023 01:00 ET | AstriVax
The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO).The grant will be used to accelerate the development of the company’s therapeutic vaccine targeting chronic...
Featured Image for POP Biotechnologies
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
November 30, 2022 15:01 ET | POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
September 20, 2022 21:31 ET | POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...